Destiny-breast01 nct03248492
WebDec 2, 2024 · DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC).We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. WebSep 1, 2024 · The DESTINY-Breast01 study is a clinical study in participants with a type of breast cancer called HER2-positive breast cancer. The participants in the study received a treatment called trastuzumab deruxtecan, also known as T-DXd.
Destiny-breast01 nct03248492
Did you know?
WebT-DXd has been approved for HER2-positive metastatic breast cancer and for HER2-positive metastatic gastric cancer. The approval in breast cancer was based on results from the DESTINY-Breast01 (U201; NCT03248492) and J101 (NCT02564900) trials. Here, we present dose justification for the approved 5.4 mg/kg every-3-weeks (Q3W) dose based … WebFeb 2, 2024 · (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) Approximately 15 to 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). 1–3 The recommended first-line therapy for HER2-positive …
WebJul 8, 2024 · Krop et al. conducted a phase 2 DESTINY-Breast01 (NCT03248492) study in which 253 patients with metastatic HER2-positive breast cancer previously treated with T-DM1 were included [3]. Median age of the patients was 55 years, 34.2% was Asian, 28.8% North American, and 37% European; 52.7% was HER2+ and 45.1% was HER2- (of … WebNov 8, 2024 · In the phase 2 DESTINY-Breast01 trial (NCT03248492), investigators reported a median progression-free survival (PFS) of 16.4 months among 184 heavily pretreated patients. Responses were observed in 112 patients (60.9%); the disease control rate was 97.3%. 2
WebNCT03248492 Other Study ID Numbers: DS8201-A-U201 2016-004986-18 ( EudraCT Number ) JapicCTI-173693(en) ( Registry Identifier: JapicCTI ) DESTINY-Breast01 ( Other Identifier: Daiichi Sankyo and AstraZeneca ) First Submitted: August 10, 2024: First Posted: August 14, 2024: Results First Submitted: January 17, 2024: Results First Posted: … WebJul 14, 2024 · The landmark phase 2 DESTINY-Breast01 trial (NCT03248492), showed that T-DXd had an objective response rate (ORR) of 61.4% and median progression-free survival (mPFS) of 19.4 months in patients with previously treated HER2+ advanced or metastatic breast cancer [2,3]. The trial allowed enrollment of patients with stable brain metastases, …
WebBackground: DESTINY-Breast01 (NCT03248492) is a phase II single-arm trial evaluating trastuzumab deruxtecan (T-DXd) in adults with human epidermal growth factor receptor 2-positive (HER2+) unresectable or metastatic breast cancer (u/mBC) who have received two or more prior anti-HER2 therapies. Objectives: Objectives were to explore approaches …
WebFeb 15, 2024 · DESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 registration study of T-DXd in subjects with centrally confirmed HER2-positive metastatic BC. Methods Part 1 of this 2-part study was performed in 2 stages (pharmacokinetics and dose finding; T-DXd 5.4, 6.4, 7.4 mg/kg) and served to identify … dianella heights primaryWebFeb 2, 2024 · (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) Approximately 15 to 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). 1–3 The recommended first-line therapy for HER2-positive … dianella child healthWebAug 5, 2024 · In the DESTINY-Breast01 phase II trial (NCT03248492), T-DXd demonstrated high rates of durable responses in heavily pretreated patients with HER2-positive mBC, with a confirmed objective response rate of 62%, median duration of response of 18.2 months, and median progression-free survival of 19.4 months. In addition to efficacy, successful ... citenship in society merit badge scout smartsWebSep 18, 2024 · “In comparison trastuzumab deruxtecan had a risk of [10.5%], so 5-fold higher than T-DM1, but lower than that seen inn DESTINY-Breast01 [NCT03248492].” Most importantly, Modi added, no grade 4 or 5 ILD/pneumonitis events were observed, “a major difference from DESTINY-Breast01 and a major relief.” cite northouse leadership theory and practiceWebJul 14, 2024 · Pooling data from August 2015 to June 2024 (61 patients participated in phase 1 studies DS8201-A-J101 [NCT02564900], and DS8201-A-A104 [NCT03383692], and 184 patients were in the phase 2 DESTINY-Breast01 study [NCT03248492]), including this update from ASCO, indicated that ILD occurred in 15.5% of patients with HER2 … dianella heights ymcaWeb在 DESTINY-Breast01和DS8201-A-J101研究(NCT02564900)中,对234名接受了至少一剂曲妥珠单抗重组冻干粉注射剂 5.4mg/kg的不可切除或转移性HER2阳性乳腺癌患者的汇总分析中评估了安全性。曲妥珠单抗重组冻干粉注射剂i最常见的不良反应(频率≥20%)为恶心、疲劳、呕吐、脱发 ... citeoffice.citedesmetiers.frWebSep 18, 2024 · This is the first report of DESTINY-Breast03 (NCT03529110), a multicenter, open-label, randomized phase 3 study comparing the efficacy and safety of T-DXd vs T-DM1 in pts with HER2+ mBC previously treated with trastuzumab and taxane. This is the first reported randomized study of T-DXd in BC. dianella plenty valley community health